Unichem LaboratoriesNSE:UNICHEMLAB -0.13%65 PB Ratio is 1.12 as of Jun. 26, 2026, which is 13% above its 10-year median of 0.99. GuruFocus rates NSE:UNICHEMLAB with a GF Score™ of 65/100 and a GF Value™ of ₹686.53 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Unichem Laboratories ranks better than 71.04% on this metric.
The historical rank and industry rank for Unichem Laboratories's PB Ratio or its related term are showing as below:
NSE:UNICHEMLAB'
s PB Ratio Range Over the Past 10 Years
Min: 0.35 Med: 0.99 Max: 2.83
Current: 1.12
During the past 13 years, Unichem Laboratories's highest PB Ratio was 2.83. The lowest was 0.35. And the median was 0.99.
NSE:UNICHEMLAB's PB Ratio is ranked better than 71.04% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs NSE:UNICHEMLAB: 1.12
During the past 12 months, Unichem Laboratories's average Book Value Per Share Growth Rate was 10.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 0.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 10.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Unichem Laboratories was 57.30% per year. The lowest was -2.20% per year. And the median was 9.45% per year.
Back to Basics: PB Ratio
Unichem Laboratories (NSE:UNICHEMLAB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Unichem Laboratories PB Ratio Related Terms
Unichem Laboratories PB Ratio Historical Data
* Premium members only.
The historical data trend for Unichem Laboratories's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unichem Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unichem Laboratories PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unichem Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Unichem Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Unichem Laboratories (NSE:UNICHEMLAB) has a PB Ratio of 1.12 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Unichem Laboratories and its competitors. This is 13% above median its historical median of 0.99. Over the past decade, Unichem Laboratories' PB Ratio has ranged from 0.35 to 2.83. According to the industry distribution chart, Unichem Laboratories ranks #267 out of 922 companies in the Drug Manufacturers industry, placing it in the top 29%.
Is Unichem Laboratories' PB Ratio too high?
Unichem Laboratories' current PB Ratio of 1.12 is 13% above median its 10-year median of 0.99. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 2.83. The Drug Manufacturers industry median PB Ratio is 1.83. Unichem Laboratories' value of 1.12 is 38.6% below this industry median. Based on the distribution chart, Unichem Laboratories ranks #267 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Unichem Laboratories has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Unichem Laboratories' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Unichem Laboratories ranks #267 out of 922 companies for PB Ratio. This puts Unichem Laboratories in the upper half of its industry. The industry median PB Ratio is 1.83. Unichem Laboratories' value of 1.12 is 38.6% below this benchmark. Historically, Unichem Laboratories' own PB Ratio has ranged from 0.35 to 2.83 over the past decade. While the company's 10-year median is 0.99 vs. the industry median of 1.83, Unichem Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unichem Laboratories's current PB Ratio of 1.12 is 38.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Unichem Laboratories and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unichem Laboratories's current PB Ratio is 1.12, which is 13% above median its own 10-year median of 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unichem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Unichem Laboratories (NSE:UNICHEMLAB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹686.53, compared to a current price of ₹433.00 — trading 36.9% below its estimated fair value. The current PB Ratio is 1.12, which is 13% above median its 10-year median of 0.99 and 38.6% below the Drug Manufacturers industry median of 1.83. Unichem Laboratories' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Unichem Laboratories (NSE:UNICHEMLAB), the current PB Ratio is 1.12 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unichem Laboratories (NSE:UNICHEMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Unichem Laboratories stock appears to be undervalued.
The current stock price of ₹433.00 is trading 36.9% below its estimated GF Value™ of ₹686.53.
GuruFocus considers Unichem Laboratories to be Significantly Undervalued.
Key valuation signals for NSE:UNICHEMLAB:
PB Ratio: 1.12 (13% above median its 10-year median of 0.99)
GF Value™: ₹686.53 vs. price of ₹433.00 (36.9% below fair value)
Industry Position: 38.6% below the Drug Manufacturers median (#267 of 922)
No single metric tells the full story. See the NSE:UNICHEMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.
65GF Score
Get the complete analysis for NSE:UNICHEMLAB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:UNICHEMLAB has been successfully added to your 
